Published :
Tables : 46
Figures : 43
Category : Healthcare
No. of Pages : 216
Report Code : HC-1126
Immune repertoire sequencing market is poised to value USD 136 million in 2022, growing at a CAGR of 7.1% during the forecast period 2022 to 2028. Immune repertoire describes the sub-types of proteins that the immune system of an organism produces. Six essential protein types make up the immune systems of vertebrates: two immunoglobulin and four T cell receptors. Researchers and scientists can analyse and comprehend diseases caused by adaptive immune systems thanks to immune repertoire sequencing. Immune repertoire sequencing has broad applications in the discovery of biomarkers, the study of infectious diseases, the study of asthma and allergies, and the study of cancer immunotherapy. To increase the efficiency and cost-effectiveness of rational medication development, immune repertoire sequencing is widely used in biomarker discovery. T cell receptor-beta sequencing services are now available through the Center for Commercialization of Cancer Immunotherapy (C3iBiomarker )'s and Diagnostic unit. Immune repertoire sequencing is helpful in locating the specific antigen information contained in lymphocytes and in comprehending the body's defences against intruders. Immune repertoire sequencing is used for a variety of purposes, such as the discovery of biomarkers, cancer immunotherapy, the investigation of allergies and asthma, and the study of infectious diseases. The usage of immune repertoire sequencing is growing as a result of an increase in the number of novel product launches, product development R&D, and cancer patients. The market's growth will be fueled by these elements as well as increasing government backing. Numerous organisations will keep looking for solutions for immune system biomarkers during the projected period in an effort to create new opportunities for the immunological repertoire sequencing market. The market for immune repertoire sequencing is anticipated to develop as a result of rising demand for customised medicine, which analyses a person's genetic profile to inform decisions about the diagnosis, prevention, and treatment of illnesses. FutureWise Market Research has instantiated a report that provides an intricate analysis of Immune Repertoire Sequencing Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. According to the research study conducted by FutureWise research analysts, the Immune Repertoire Sequencing Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Prominent players of the market are: ABVITRO (NOW JUNO THERAPEUTICS), ADAPTIVE BIOTECHNOLOGIES, AGILENT TECHNOLOGIES, ARCHERDX, INC., BGI, ILLUMINA, INC., IREPERTOIRE, INC., OXFORD NANOPORE TECHNOLOGIES, LTD, PACIFIC BIOSCIENCES, Qiagen N.V., Takara Bio Inc., CD Genomics, Roche Holding AG and Thermo Fisher Scientific Immune Repertoire Sequencing Market Segmentation: By Product • Instrument o NGS o PCR • Assay, Kits and Reagent o TCR Kits • Human TCR Kits • Mouse TCR Kits o BCR Kits • Human BCR Kits • Mouse BCR Kits • Analytical Software o TCR Analysis Solutions o BCR Analysis Solutions o TCR & BCR Analysis Solutions • Services o Pre-Sequencing Services o Sequencing Services o Data Analysis Services By Application Biomarker Discovery Autoimmune Diseases Cancer Immunotherapy Infectious Disease Research Asthma and Allergy Research Vaccine Development Immunodeficiency Identification Others (If Any) By End User Diagnostic Labs Pharmaceutical and Biotech Companies Research Institutes Others (If Any) By Region North America Europe Asia-Pacific Latin America Middle East and Africa Immune Repertoire Sequencing Market Sample Video: Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the immune repertoire sequencing market based on by products, by application, by end users and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions • Profiling of companies to evaluate their market shares, strategies, financials and core competencies Flexible Delivery Model We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization Mobility Care offered are free of charge with purchase of any license of the report You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Immune repertoire describes the sub-types of proteins that the immune system of an organism produces. Six essential protein types make up the immune systems of vertebrates: two immunoglobulin and four T cell receptors. Researchers and scientists can analyse and comprehend diseases caused by adaptive immune systems thanks to immune repertoire sequencing. Immune repertoire sequencing has broad applications in the discovery of biomarkers, the study of infectious diseases, the study of asthma and allergies, and the study of cancer immunotherapy. To increase the efficiency and cost-effectiveness of rational medication development, immune repertoire sequencing is widely used in biomarker discovery. T cell receptor-beta sequencing services are now available through the Center for Commercialization of Cancer Immunotherapy (C3iBiomarker )'s and Diagnostic unit. Immune repertoire sequencing is helpful in locating the specific antigen information contained in lymphocytes and in comprehending the body's defences against intruders. Immune repertoire sequencing is used for a variety of purposes, such as the discovery of biomarkers, cancer immunotherapy, the investigation of allergies and asthma, and the study of infectious diseases. The usage of immune repertoire sequencing is growing as a result of an increase in the number of novel product launches, product development R&D, and cancer patients. The market's growth will be fueled by these elements as well as increasing government backing. Numerous organisations will keep looking for solutions for immune system biomarkers during the projected period in an effort to create new opportunities for the immunological repertoire sequencing market. The market for immune repertoire sequencing is anticipated to develop as a result of rising demand for customised medicine, which analyses a person's genetic profile to inform decisions about the diagnosis, prevention, and treatment of illnesses.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Immune Repertoire Sequencing Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Immune Repertoire Sequencing Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.
Prominent players of the market are:
ABVITRO (NOW JUNO THERAPEUTICS), ADAPTIVE BIOTECHNOLOGIES, AGILENT TECHNOLOGIES, ARCHERDX, INC., BGI, ILLUMINA, INC., IREPERTOIRE, INC., OXFORD NANOPORE TECHNOLOGIES, LTD, PACIFIC BIOSCIENCES, Qiagen N.V., Takara Bio Inc., CD Genomics, Roche Holding AG and Thermo Fisher Scientific
Immune Repertoire Sequencing Market Segmentation:
By Product
• Instrument o NGS o PCR • Assay, Kits and Reagent o TCR Kits • Human TCR Kits • Mouse TCR Kits o BCR Kits • Human BCR Kits • Mouse BCR Kits • Analytical Software o TCR Analysis Solutions o BCR Analysis Solutions o TCR & BCR Analysis Solutions • Services o Pre-Sequencing Services o Sequencing Services o Data Analysis Services
By Application
By End User
By Region
Immune Repertoire Sequencing Market Sample Video:
Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants
FutureWise Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data points affecting market growth
Objectives of the Study: • To provide with an exhaustive analysis on the immune repertoire sequencing market based on by products, by application, by end users and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions • Profiling of companies to evaluate their market shares, strategies, financials and core competencies
Flexible Delivery Model
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Immune Repertoire Sequencing Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Immune Repertoire Sequencing Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Immune Repertoire Sequencing Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Immune Repertoire Sequencing Market, By Product Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Instrument 7.1.1. NGS 7.1.2. PCR 7.2. Assay, Kits and Reagent 7.2.1. TCR Kits 7.2.1.1. Human TCR Kits 7.2.1.2. Mouse TCR Kits 7.2.2. BCR Kits 7.2.2.1. Human BCR Kits 7.2.2.2. Mouse BCR Kits 7.3. Analytical Software 7.3.1. TCR Analysis Solutions 7.3.2. BCR Analysis Solutions 7.3.3. TCR & BCR Analysis Solutions 7.4. Services 7.4.1. Pre-Sequencing Services 7.4.2. Sequencing Services 7.4.3. Data Analysis Services 8. Immune Repertoire Sequencing Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Biomarker Discovery 8.2. Autoimmune Diseases 8.3. Cancer Immunotherapy 8.4. Infectious Disease Research 8.5. Asthma and Allergy Research 8.6. Vaccine Development 8.7. Immunodeficiency Identification 8.8. Others (If Any) 9. Immune Repertoire Sequencing Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Diagnostic Labs 9.2. Pharmaceutical and Biotech Companies 9.3. Research Institutes 9.4. Others (If Any) 10. North America Immune Repertoire Sequencing Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2022-2028 11. Latin America Immune Repertoire Sequencing Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Brazil 11.2.2. Venezuela 11.2.3. Argentina 11.2.4. Rest of Latin America 11.3. Market Size (USD Million) Forecast for Latin America 2022-2028 12. Europe Immune Repertoire Sequencing Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Rest of Europe 12.3. Market Size (USD Million) Forecast for Europe 2022-2028 13. Asia Pacific Immune Repertoire Sequencing Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Japan 13.2.2. China 13.2.3. India 13.2.4. Australia and New Zealand 13.2.5. ASEAN 13.2.6. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3. Market Size (USD Million) Forecast for MEA 2022-2028 15. Market Share Analysis and Competitive Landscape 15.1. Global Landscape - Key Players, Revenue and Presence 15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 15.3. Global Emerging Companies 15.4. North America - Market Share Analysis and Key Regional Players 15.5. Europe - Market Share Analysis and Key Regional Players 15.6. Asia Pacific - Market Share Analysis and Key Regional Players 15.7. Global Key Player - Growth Matrix 16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 16.1. ABVITRO (NOW JUNO THERAPEUTICS) 16.1.1. Company Overview 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2. ADAPTIVE BIOTECHNOLOGIES 16.2.1. Company Overview 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3. AGILENT TECHNOLOGIES 16.3.1. Company Overview 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4. ARCHERDX, INC. 16.4.1. Company Overview 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5. BGI 16.5.1. Company Overview 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6. ILLUMINA, INC. 16.6.1. Company Overview 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7. IREPERTOIRE, INC. 16.7.1. Company Overview 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 16.8. OXFORD NANOPORE TECHNOLOGIES, LTD 16.8.1. Company Overview 16.8.2. Product Portfolio 16.8.3. SWOT Analysis 16.8.4. Financial Overview 16.8.5. Strategic Overview 16.9. PACIFIC BIOSCIENCES 16.9.1. Company Overview 16.9.2. Product Portfolio 16.9.3. SWOT Analysis 16.9.4. Financial Overview 16.9.5. Strategic Overview 16.10.Qiagen N.V. 16.10.1. Company Overview 16.10.2. Product Portfolio 16.10.3. SWOT Analysis 16.10.4. Financial Overview 16.10.5. Strategic Overview 16.11.Takara Bio Inc. 16.11.1. Company Overview 16.11.2. Product Portfolio 16.11.3. SWOT Analysis 16.11.4. Financial Overview 16.11.5. Strategic Overview 16.12.Thermo Fisher Scientific 16.12.1. Company Overview 16.12.2. Product Portfolio 16.12.3. SWOT Analysis 16.12.4. Financial Overview 16.12.5. Strategic Overview 16.13.CD Genomics 16.13.1. Company Overview 16.13.2. Product Portfolio 16.13.3. SWOT Analysis 16.13.4. Financial Overview 16.13.5. Strategic Overview 16.14.Roche Holding AG 16.14.1. Company Overview 16.14.2. Product Portfolio 16.14.3. SWOT Analysis 16.14.4. Financial Overview 16.14.5. Strategic Overview 17. Pre and Post COVID-19 Impact 17.1. Positive influence on the healthcare industry 17.2. The financial disruption of the manufacturing sector 17.3. Impact of COVID-19 on emerging companies 17.4. Significant mandates in the regulations initiated by healthcare administrations 17.5. The overall economic slowdown of the developing and developed nations 18. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders
2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study
3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. Immune Repertoire Sequencing Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Immune Repertoire Sequencing Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Immune Repertoire Sequencing Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Immune Repertoire Sequencing Market, By Product Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Instrument 7.1.1. NGS 7.1.2. PCR 7.2. Assay, Kits and Reagent 7.2.1. TCR Kits 7.2.1.1. Human TCR Kits 7.2.1.2. Mouse TCR Kits 7.2.2. BCR Kits 7.2.2.1. Human BCR Kits 7.2.2.2. Mouse BCR Kits 7.3. Analytical Software 7.3.1. TCR Analysis Solutions 7.3.2. BCR Analysis Solutions 7.3.3. TCR & BCR Analysis Solutions 7.4. Services 7.4.1. Pre-Sequencing Services 7.4.2. Sequencing Services 7.4.3. Data Analysis Services
8. Immune Repertoire Sequencing Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Biomarker Discovery 8.2. Autoimmune Diseases 8.3. Cancer Immunotherapy 8.4. Infectious Disease Research 8.5. Asthma and Allergy Research 8.6. Vaccine Development 8.7. Immunodeficiency Identification 8.8. Others (If Any)
9. Immune Repertoire Sequencing Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Diagnostic Labs 9.2. Pharmaceutical and Biotech Companies 9.3. Research Institutes 9.4. Others (If Any)
10. North America Immune Repertoire Sequencing Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2022-2028
11. Latin America Immune Repertoire Sequencing Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Brazil 11.2.2. Venezuela 11.2.3. Argentina 11.2.4. Rest of Latin America 11.3. Market Size (USD Million) Forecast for Latin America 2022-2028
12. Europe Immune Repertoire Sequencing Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Rest of Europe 12.3. Market Size (USD Million) Forecast for Europe 2022-2028
13. Asia Pacific Immune Repertoire Sequencing Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Japan 13.2.2. China 13.2.3. India 13.2.4. Australia and New Zealand 13.2.5. ASEAN 13.2.6. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3. Market Size (USD Million) Forecast for MEA 2022-2028
15. Market Share Analysis and Competitive Landscape 15.1. Global Landscape - Key Players, Revenue and Presence 15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 15.3. Global Emerging Companies 15.4. North America - Market Share Analysis and Key Regional Players 15.5. Europe - Market Share Analysis and Key Regional Players 15.6. Asia Pacific - Market Share Analysis and Key Regional Players 15.7. Global Key Player - Growth Matrix
16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 16.1. ABVITRO (NOW JUNO THERAPEUTICS) 16.1.1. Company Overview 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2. ADAPTIVE BIOTECHNOLOGIES 16.2.1. Company Overview 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3. AGILENT TECHNOLOGIES 16.3.1. Company Overview 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4. ARCHERDX, INC. 16.4.1. Company Overview 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5. BGI 16.5.1. Company Overview 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6. ILLUMINA, INC. 16.6.1. Company Overview 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7. IREPERTOIRE, INC. 16.7.1. Company Overview 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 16.8. OXFORD NANOPORE TECHNOLOGIES, LTD 16.8.1. Company Overview 16.8.2. Product Portfolio 16.8.3. SWOT Analysis 16.8.4. Financial Overview 16.8.5. Strategic Overview 16.9. PACIFIC BIOSCIENCES 16.9.1. Company Overview 16.9.2. Product Portfolio 16.9.3. SWOT Analysis 16.9.4. Financial Overview 16.9.5. Strategic Overview 16.10.Qiagen N.V. 16.10.1. Company Overview 16.10.2. Product Portfolio 16.10.3. SWOT Analysis 16.10.4. Financial Overview 16.10.5. Strategic Overview 16.11.Takara Bio Inc. 16.11.1. Company Overview 16.11.2. Product Portfolio 16.11.3. SWOT Analysis 16.11.4. Financial Overview 16.11.5. Strategic Overview 16.12.Thermo Fisher Scientific 16.12.1. Company Overview 16.12.2. Product Portfolio 16.12.3. SWOT Analysis 16.12.4. Financial Overview 16.12.5. Strategic Overview 16.13.CD Genomics 16.13.1. Company Overview 16.13.2. Product Portfolio 16.13.3. SWOT Analysis 16.13.4. Financial Overview 16.13.5. Strategic Overview 16.14.Roche Holding AG 16.14.1. Company Overview 16.14.2. Product Portfolio 16.14.3. SWOT Analysis 16.14.4. Financial Overview 16.14.5. Strategic Overview
17. Pre and Post COVID-19 Impact 17.1. Positive influence on the healthcare industry 17.2. The financial disruption of the manufacturing sector 17.3. Impact of COVID-19 on emerging companies 17.4. Significant mandates in the regulations initiated by healthcare administrations 17.5. The overall economic slowdown of the developing and developed nations
18. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics